New therapies for nontuberculous mycobacterial lung infection

Sarah J. Chalmers, Timothy R. Aksamit

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE OF REVIEW: Although nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies. RECENT FINDINGS: Several new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease. SUMMARY: Promising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.

Original languageEnglish (US)
Pages (from-to)176-184
Number of pages9
JournalCurrent Opinion in Infectious Diseases
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2022

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'New therapies for nontuberculous mycobacterial lung infection'. Together they form a unique fingerprint.

Cite this